Affymax (AFFY) Announces Another Data Monitoring Committee Review of Phase 3 Hematide Program
Up)
Affymax, Inc. (Nasdaq: AFFY) announced that the independent Data Monitoring Committee, which provides oversight for the Phase 3 program for Hematide(TM), has completed another review and has informed the company that the cumulative safety data generated thus far from the EMERALD and PEARL Phase 3 trials support continuation of the studies. In the Phase 3 program, Hematide is being evaluated to treat anemia in chronic renal failure patients on dialysis and not on dialysis.
The Phase 3 program, which consists of four trials, was initiated in October 2007. Affymax announced that enrollment was complete in all four Phase 3 trials in November 2008 and reiterated its expectation for a NDA submission in 2010.
The Phase 3 program, which consists of four trials, was initiated in October 2007. Affymax announced that enrollment was complete in all four Phase 3 trials in November 2008 and reiterated its expectation for a NDA submission in 2010.
You May Also Be Interested In
- Analyst Sees Affymax's (AFFY) Omontys as Comparable to Amgen's (AMGN) Epogen; Raises AFFY Target to $21
- AVEO Oncology (AVEO) Commences AV-203 Phase 1 in Advanced Solid Tumors
- Celldex Therapeutics (CLDX) Announces 'High Response' CDX-011 Trial Data
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
